Enhanced Immune Responses against HIV-1 with Adenovector (Gag and Tat) Prime/Protein Boost Regimen and GM-CSF Injection
-
Negin Hosseini Rouzbahani
,
Saeed Bayanolhagh
,
Mohammad Gholami
,
Ali Esmaeilzadeh
,
Zahra Bayat Jozani
,
Minoo Mohraz
,
Ali Akbar Pourfathollah
Abstract
Vaccines against the HIV-1 virus offers the best hope for eliminating HIV-associated mortality. Recombinant adenovector type 5 (rAd5) vaccine is a potential candidate for preventive vaccine strategies. In this study, we evaluated the rAd5 prime/protein boost strategy in a murine model. We used rAd5 harboring single HIV-1 genes. These genes, including gag (p24) and exon1 of tat, were amplified from HIV-1 (clade A) RNA using nested PCR. Recombinant vectors were constructed, purified and then injected at 1012 viral particles into four groups, each comprising five mice. The groups were each assigned to receive one of rAd5 prime/protein boost Gag, Tat with and without recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF), and rAd5 with and without genes. The humoral responses were evaluated using ELISA and cellular immune responses checked by cell proliferation and ELISpot assays (IL-2, IL-4 and IFN-γ). It was shown that compared with the rAd5 injection alone, the rAd5 prime/protein boost plan increased cellular immunity (p= 0.009) as well as humoral immunity (p= 0.009). Moreover, rGM-CSF as an adjuvant enhanced cell-mediated immunity and increased IL-4 expression (p=0.032). The results revealed that the simultaneous use of multiple antigens and heterologous prime/boost strategy can enhance both humoral and cellular immune systems. Moreover, subcutaneous injection of rGM-CSF increases IL-4 production and shifts the immune pattern to Th2. These strategies can potentially be used to develop an efficient HIV-1 vaccine.
1. UNAIDS (2013) Report on the global HIV/AIDS epidemic. (UNAIDS, Geneva, Switzerland).2. Fauci AS, Pantaleo G, Stanley S, Weissman D.Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996; 124(7):654-63.
3. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 2003;9(7):861-6.
4. Smith DH, Winters-Digiacinto P, Mitiku M, O'Rourke S, Sinangil F, Wrin T, et al. Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. PLoS One 2010; 5(8):e12076.
5. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK,Desrosiers RC. Protective effects of a live attenuated SIVvaccine with a deletion in the nef gene. Science 1992;258(5090):1938-41.
6. Lanza P, Moss RB, Giermakowska W, Hancock RB, Richieri SP, Theofa G, et al. Whole-killed gp120- depleted HIV-1 antigen in a murine model for prophylactic vaccination. Vaccine 1998; 16(7):727-31.
7. Weissburg RP, Berman PW, Cleland JL, Eastman D, Farina F, Frie S, et al. Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharm Res 1995; 12(10):1439-46.
8. Ugen KE, Nyland SB,Boyer JD, Vidal C, Lera L,Rasheid S, et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 1998; 16(19):1818-21.
9. Mehendale S, Sahay S, Thakar M, Sahasrabuddhe S, Kakade M, Shete A, et al. Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India. Indian J Med Res 2010; 132:168-75.
10. Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010; 5(9):e12873.
11. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392(6673):245-52.
12. Shiver JW, Fu T-M,Chen L, Casimiro DR, Davies M-E, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency- virus immunity. Nature 2002; 415(6869):331-5.
13. Kostense S, Koudstaal W, Sprangers M, Weverling GJ,Penders G, Helmus N, et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004; 18(8):1213-6.
14. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21(4):163-5.
15. Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U, et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002; 168(9):4391-8.
16. Wu L, Kong WP, Nabel GJ. Enhanced breadth of CD4 T- cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 2005; 79(13):8024-31.
17. Patterson LJ, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B, et al. Potent, Persistent Induction and Modulation of Cellular Immune Responses in Rhesus Macaques Primed with Ad5hr-Simian Immunodeficiency Virus (SIV) env/rev, gag, and/or nef Vaccines and Boosted with SIV gp120. J Virol 2003; 77(16):8607-20.
18. Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 2005;79(2):771-9.
19. Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999;39(4):291-7.
20. Kameoka M, Rong L, Gotte M, Liang C, Russell RS, Wainberg MA. Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication. J Virol 2001; 75(6):2675-83.
21. Khoja S, Ojwang P, Khan S, Okinda N, Harania R, Ali S.Genetic analysis of HIV-1 subtypes in Nairobi, Kenya. PLoS One 2008; 3(9):e3191.
22. Van Laethem K ,Beuselinck K, Van Dooren S, De Clercq E, Desmyter J, Vandamme AM. Diagnosis of human immunodeficiency virus infection by a polymerase chain reaction assay evaluated in patients harbouring strains of diverse geographical origin. J Virol Methods 1998;70(2):153-66.
23. Zuber B,Bottiger D,Benthin R,ten Haaft P,Heeney J,Wahren B, et al. An in vivo model for HIV resistance development. AIDS Res Hum Retroviruses 2001;17(7):631-5.
24. Shafer RW, Warford A, Winters MA, Gonzales MJ.Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals. J Virol Methods 2000; 86(2):143-53.
25. Bayanolhagh S, Alinezhad M, Kamali K, Foroughi M, Khorram Khorshid HR, Mohraz M, et al. Characterization of immune responses induced by combined Clade-A HIV-1 recombinant Adenovectors in mice. Iran J Immunol 2010; 7(3):162-76.
26. Catanzaro, A. T, Koup, R. A, Roederer, M, Bailer, R. T, Enama, M. E, Moodie, Z , et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006;194(12):1638-49.
27. Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 2006; 177(6):4028-36.
28. Riviere Y, Tanneau-Salvadori F, Regnault A, Lopez O, Sansonetti P, Guy B, et al. Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol 1989;63(5):2270-7.
29. Buseyne F, McChesney M, Porrot F, Kovarik S, Guy B, Riviere Y. Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein. J Virol. 1993; 67(2):694-702.
30. Stevceva L, Tryniszewska E, Hel Z, Nacsa J, Kelsall B, Washington Parks R, et al. Differences in time of virus appearance in the blood and virus-specific immune responses in intravenous and intrarectal primary SIVmac251 infection of rhesus macaques; a pilot study. BMC Infect Dis 2001; 1:9.
31. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A, et al. Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses. J Immunol 2002; 168(1):197-206.
32. Secchiero P, Zella D, Capitani S, Gallo RC, Zauli G.Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. J Immunol 1999; 162(4):2427-31.
33. Kaiko GE, Horyat JC, Beagley KW, Hansbro PM.Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology 2008; 123(3):326–38.
34. Evans T G, Fitzgerald T, Gibbons D C, Keefer M C, and Soucier H. Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. Clin Exp Immunol 1998; 111(2):243–50.
35. Amara RR, Villinger F, Staprans SI, Altman JD, Montefiori DC, Kozyr NL, et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002; 76(15):7625-31.
36. Graham BS, Matthews TJ, Belshe RB, Clements ML,Dolin R, Wright PF, et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis 1993;167(3):533-7.
37. McConnell MJ, Hanna PC, Imperiale MJ. Adenovirus- based prime-boost immunization for rapid vaccination against anthrax. Mol Ther 2007; 15(1):203-10.
38. Shu Y, Winfrey S, Yang ZY, Xu L, Rao SS, Srivastava I,et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 2007; 25(8):1398-408.
39. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, et al. Granulocyte-macrophage colony- stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996; 88(1):202-10.
40. Billaut-Mulot O, Idziorek T, Ban E, Kremer L, Dupre L, Loyens M, et al. Interleukin-18 modulates immune responses induced by HIV-1 Nef DNA prime/protein boost vaccine. Vaccine 2000; 19(1):95-102.
41. Wing E, Magee D, Whiteside T, Kaplan S, Shadduck R.Recombinant human granulocyte/macrophage colony- stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood 1989; 73(3):643-6.
42. Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S, et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000; 164(6):3102-11.
43. Kaplan G, Walsh G, Guido LS, Meyn P, Burkhardt RA, Abalos RM, et al. Novel responses of human skin to intradermal recombinant granulocyte/macrophage- colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 1992; 175(6):1717-28.
44. Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, et al. Potent CD4+ T Cell Responses Elicited by a Bicistronic HIV-1 DNA Vaccine Expressing gp120 and GM-CSF. J Immunol 2002; 168(2):562-8.
| Files | ||
| Issue | Vol 15, No 5 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Adenovirus HIV vaccine Multiple antigen Prime-boost rGM-CSF | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
